Patent Strategy

Lipigon's patent strategy aims to establish strong protection for the company's current and future products in development and their medical use. Lipigon's existing patent portfolio illustrates how multiple projects can be developed through a structured patent strategy.

In November 2019, applications for three different patents under the Patent Cooperation Treaty (PCT) were filed for P1, Lipisense®, which were later consolidated into a single patent family currently in the national phase in several countries. New development projects closely related to P1 are in the planning stage, and P4, CAP, utilizes parts of this patent family. In P4, substances targeting the ANGPTL4 protein, already optimized in P1, are being effectively used.

In October 2023, Lipigon was granted a patent by the United States Patent and Trademark Office (USPTO) for Lipisense®, concerning the treatment of cardiometabolic diseases (cardiovascular diseases and metabolic conditions such as type 2 diabetes).

For the out-licensed P2 project, Lipodystrophy, CombiGene AB (publ) is the applicant of a patent filed in August 2020. This application is published as WO 2022/043676.

Within P3, Dyslipidemia, patent applications to protect specific substances will filed after the completion of chemical optimization. In instances where Lipigon will engage in orphan drug development, efforts to obtain orphan drug status will be pursued.

Patent Application Number:

PCT/EP2019/081161 published as WO 2020/099478.